Address
304 North Cardinal St.
Dorchester Center, MA 02124
Work Hours
Monday to Friday: 7AM - 7PM
Weekend: 10AM - 5PM
TALETE’S AIM
To overcome Acute Myeloyd Leukemia resistance by targeting the immune microenvironment, enhancing therapies, and developing precision biomarkers.
Decoding the AML microenvironment
Identify and validate bone marrow immune and stromal cell subsets through advanced multi-omics techniques, unraveling their role in therapy resistance.
Unveiling immune mechanisms
Investigate leukemia microenvironment interactions via single-cell analyses and mass cytometry, focusing on pathways like IDO1 and PD-1 to identify targets for therapeutic intervention.
Driving precision medicine:
Develop non-invasive biomarkers using liquid biopsy technology to predict patient response and guide personalized treatment strategies.
TALETE CONSORTIUM
IRCCS Azienda Ospedaliero-Universitaria di Bologna
IRCCS Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori” (IRST)
German Cancer Research Center, DKFZ
University of Bergen Faculty of Medicine (UiB)
University of Latvia (UL)
Centre National de la Recherche Scientifique (CNRS) – Centre d’Immunologie de Marseille Luminy (CIML) – Marseille
A consortium focused on innovation for patients
Why we have created TALETE project?
AML in elderly patients has poor outcomes due to therapy resistance driven by the immune-suppressive microenvironment. TALETE addresses this challenge by targeting these mechanisms and enhancing treatment strategies.
UNMET NEEDS
Current therapies for elderly AML patients, particularly in relapsed cases, are inadequate. TALETE addresses this gap by pioneering novel immunotherapy approaches.
INNOVATIVE FOCUS
Unlike traditional studies, TALETE emphasizes the AML microenvironment, specifically immune and stromal cell contributions, as key players in treatment failure.
POTENTIAL FOR BREAKTHROUGHS
By integrating new compounds with existing backbone therapies (azacitidine and venetoclax), TALETE seeks to enhance efficacy and overcome resistance in AML patients.
Do you have any question?
Feel free to contact us anytime.
Advancing AML therapies through innovative models
From lab to life: functional validation of AML data Understanding AML resistance is only part of the battle. Translating this knowledge into actionable therapies is where the TALETE project truly shines. By employing sophisticated in vitro models, we are validating our findings and exploring new treatment approaches. These models replicate AML interactions with the BM…
Decoding the bone marrow microenvironment in Acute Myeloid Leukemia
Understanding AML resistance Acute Myeloid Leukemia (AML) remains one of the most challenging cancers to treat, especially in elderly patients. Resistance to treatment often stems from the bone marrow (BM) microenvironment, a complex network of immune and stromal cells that fosters tumor survival and shields it from therapy. The TALETE project is at the forefront…
Exploring immune responses in AML treatments
The immune microenvironment: a key to better treatments Immunotherapy is revolutionizing cancer treatment, but its success in AML has been limited. The TALETE project is tackling this challenge by focusing on how the immune microenvironment responds to azacitidine and venetoclax, two frontline treatments for AML. Central to our research are pathways like AHR and IFN-γ,…
